Bacteremia due to Brevundimonas vesicularis  by Lin, Chun-Yu & Chen, Yen-Hsu
Journal of Microbiology, Immunology and Infection (2013) 46, 143Available online at www.sciencedirect.com
journal homepage: www.e- jmii .comLETTER TO THE EDITORBacteremia due to Brevundimonas vesicularisTo the Editor,
In the original article on Brevundimonas vesicularis bacter-
emia, Zhang et al1 described the clinical characteristics and
microbiological features of 22 patients with primary B.
vesicularis bacteremia who were being treated in a medical
center in southern Taiwan during 2006e2009. In this study,
microbiological identification was performed with an API 20
NE system (bioMe´rieux, Marcy L’etoile, France) or Phoenix-
100 automated system (Becton, Dickinson, and Company,
Sparks, MD, USA). However, there are some differences be-
tween commercial automated identification methods and
16s rRNA gene sequencing, as shown in another case series
study conducted in Taiwan.2 Of the four strains identified as
B. vesicularis by the Phoenix system, three were finally
confirmed as Brevundimonas nasdae and one as Brevundi-
monas diminuta by the 16s rRNA gene sequencing. Again,
four isolates were identified as B. diminuta or B. vesicularis
by the VITEK 2 system (bioMe´rieux), which were finally
confirmed as B. nasdae by 16s rRNA gene sequencing.
Therefore, in addition to commercial identification
methods, further identification by amolecularmethodmightTable 1 In vitro antimicrobial susceptibility rates of
bacteremicBrevundimonas isolates from three cases (NZ 59)
Percentage of isolates
susceptible to indicated agent
Zhang et al1
(n Z 22)
Lee et al2,a
(n Z 30)
Shang et al3,b
(n Z 7)
Ceftazidime 63.6 100 42.9
Cefepime NA 27 66.6
Cefpirome 90.9 NA NA
Amikacin 86.4 100 100
Piperacillin/
tazobactam
90.9 100 100
Ciprofloxacin 86.4 0 33.3
TMP/SMZ 59.1 NA 100
NAZnot available; TMP/SMZZ trimethoprimesulfamethoxazole.
a Blood isolates of Brevundimonas species.
b Several isolates from blood without susceptibility data were
available in this case series.
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et al3 reported 15 patients infected with B. vesicularis,
including 10 patients with bacteremia. The susceptibility
profiles varied for these three case series (Table 1). For the
clinical outcomes, a low mortality rate was reported by
Zhang et al1 (22 cases with bacteremia) and Shang et al3 (10
cases with bacteremia) in patients with B. vesicularis
bacteremia (3.1%; 1/32), even without an appropriate
empiric antibiotic therapy, whereas a higher mortality rate
(18.2%; 4/22) was reported by Lee et al.2 Therefore, further
investigation is required to establish the effective thera-
peutic strategy for invasive infections and bacteremia.References
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